Enhancing RNA vaccine safety through localized delivery strategies

Taishi Kimura

20 March 2025

Viewpoint

The promise and predicament of combining adjuvants in vaccines

Ari Joffe

14 February 2025

Viewpoint

Prospects for an adult combination respiratory vaccine: the clinician’s view

Angela Branche

14 February 2025

Viewpoint

Strengthening cold chain maintenance systems in resource-constrained environments: insights from Nigeria

Tahir Buhari

19 November 2024

Viewpoint

Navigating the mRNA-LNP patent labyrinth: advice for developers

Dan Shores

07 November 2024

Viewpoint

History is the best teacher: what can RNA manufacturers learn from the challenges and successes of traditional biologics?

Adam Brown

01 November 2024

Viewpoint

Innovations in passive immunization in the fight against serious infectious diseases

Tonya Villafana

24 September 2024

Viewpoint

Large animal virus challenge models in vaccine development: a One Health approach

Sara Louise Cosby

12 September 2024

Viewpoint

Understanding vaccine hesitancy: a call for more social science in RNA vaccine research

Heidi Larson

21 May 2024

Viewpoint

Swiss regulatory aspects and evaluation considerations for ATMPs and other nucleic acid-based products such as mRNA-based vaccines

Julia Djonova

15 May 2024

Viewpoint

How can investing in technology transfers help build a sustainable manufacturing ecosystem? An example from cholera

Jeanette Hayes, Charlotte Weller

12 April 2024

Viewpoint

The power of plants as vaccine production platforms

Kathleen Hefferon

12 April 2024

Viewpoint

Regulatory strategies for developing and manufacturing RNA-LNPs

Alexander Aust

05 April 2024

Viewpoint

Overcoming challenges in technology transfer within the vaccine industry

Anubhaw Kumar Singh

28 March 2024

Viewpoint

Human capital comes with a memory

Helena Strigard

25 March 2024

Viewpoint

Shaping immunity against infectious diseases with multivalent DNA vaccines

Ami Patel

15 February 2024

Viewpoint

Progress and future directions for RSV prevention in older adults

Angela Branche

15 February 2024

Viewpoint

What’s next for COVID vaccines?

Jeffrey Ulmer, Lbachir BenMohamed

09 February 2024

Viewpoint

Whole-cell pneumococcal vaccines: a future-proof approach to overcoming pneumococcal serotype replacement

E Brazel, M Alsharifi, L Giorgio et al

07 February 2024

Viewpoint

Navigating vaccine distribution: tools to increase vaccine equity

Rebecca Weintraub

05 January 2024

Viewpoint

Germany supports the African Agenda of building local vaccine manufacturing capacity

Manuel Batz

20 December 2023

Viewpoint